The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature
Abstract
Major risks conferred by BRCA1 and BRCA2 in women are for cancers of the breast, ovary, fallopian tube, and peritoneum. Male carriers of mutations in BRCA1 or BRCA2 are also susceptible to cancer; however, their risks remain poorly understood and their optimal clinical management has not yet been defined. This article reviews studies that estimate risk associated with mutations in BRCA1 or BRCA2, with a focus on the cancer sites most relevant to men. Male BRCA1 mutation carriers are at increased risk of cancers of the prostate and breast. Evidence supporting increased susceptibility to colon cancer is limited. In contrast to women, who have a greater lifetime risk of cancer with mutations of the BRCA1 gene, BRCA2 is the more important gene for men. The spectrum of cancers is wide for BRCA2 and some studies report that the overall cancer risk for male BRCA2 carriers exceeds the risk for female carriers. In particular, the relative risk to male BRCA2 mutation carriers is high before age 65 years, largely attributable to breast, prostate, and pancreatic cancers. BRCA2 mutation carriers are also at risk of stomach cancer and melanoma (of the skin and eye). Additional research into risks to male BRCA1 or BRCA2 mutation carriers is necessary, specifically to determine the magnitude of excess cancer risk among BRCA2 carriers and to increase our understanding of the basis for the observed site-specificity in cancer development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071
Self-citationIdentification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Self-citationStatistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,592
The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
WINAWER, S. (2003) · Gastroenterology · doi:10.1053/gast.2003.50044 · Cited by 2,143
Localization of a Breast Cancer Susceptibility Gene, BRCA2 , to Chromosome 13q12-13
Wooster, R., Neuhausen, S. L., Mangion, J., Quirk, Y., Ford, D., Collins, N., Nguyen, K., Seal, S., Tran, T., Averill, D., et al. (1994) · Science · doi:10.1126/science.8091231 · Cited by 1,924
Self-citationRisks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Cancer Risks in BRCA2 Mutation Carriers
Breast Cancer Linkage Consortium, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,527
Cancer Incidence in BRCA1 Mutation Carriers
Thompson, D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1358 · Cited by 1,096
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Kwan, E., Jack, E., Vesprini, D. J., Kuperstein, G., Abrahamson, J. L. A., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318787 · Cited by 986
Self-citationBurke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
Frank, T. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1480 · Cited by 812
Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2
Roa, B. B., Boyd, A. A., Volcik, K., & Richards, C. S. (1996) · Nature Genetics · doi:10.1038/ng1096-185 · Cited by 770
Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program
Brose, M. S. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1365 · Cited by 728
Struewing, J. P., Abeliovich, D., Peretz, T., Avishai, N., Kaback, M. M., Collins, F. S., & Brody, L. C. (1995) · Nature Genetics · doi:10.1038/ng1095-198 · Cited by 647
Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
Goggins, M., Schutte, M. E. M., Lü, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., Yeo, C. J., Jackson, C. E., Lynch, H. T., Hruban, R. H., et al. (1996) · PubMed · Cited by 642
Frank, T. S., Deffenbaugh, A. M., Reid, J. E., Hulick, M., Ward, B. E., Lingenfelter, B., Gumpper, K. L., Scholl, T., Tavtigian, S. V., Pruss, D. R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1480 · Cited by 558
Variation in Cancer Risks, by Mutation Position, in BRCA2 Mutation Carriers
Thompson, D., & Easton, D. (2001) · The American Journal of Human Genetics · doi:10.1086/318181 · Cited by 489
BRCA2 germline mutations in familial pancreatic carcinoma
Hahn, S. A., Greenhalf, B., Ellis, I., Sina-Frey, M., Rieder, H., Korte, B., Gerdes, B., Kress, R., Ziegler, A., Raeburn, J. A., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.3.214 · Cited by 480
Gayther, S. A., Mangion, J., Russell, P., Seal, S., Barfoot, R., Ponder, B. A. J., Stratton, M. R., & Easton, D. (1997) · Nature Genetics · doi:10.1038/ng0197-103 · Cited by 442
Murphy, K. M., Brune, K. A., Griffin, C. A., Sollenberger, J. E., Petersen, G. M., Bansal, R. K., Hruban, R. H., & Kern, S. E. (2002) · PubMed · Cited by 435
Cancer Risks in Two Large Breast Cancer Families Linked to BRCA2 on Chromosome 13q12‐13
Easton, D. F., Steele, L., Fields, P., Ormiston, W., Averill, D., Daly, P. A., McManus, R., Neuhausen, S. L., Ford, D., Wooster, R., et al. (1997) · The American Journal of Human Genetics · doi:10.1086/513891 · Cited by 387
Oddoux, C., Struewing, J. P., Clayton, C. M., Neuhausen, S., Brody, L. C., Kaback, M., Haas, B., Norton, L., Borgen, P., Jhanwar, S., et al. (1996) · Nature Genetics · doi:10.1038/ng1096-188 · Cited by 381
Two Percent of Men with Early-Onset Prostate Cancer Harbor Germline Mutations in the BRCA2 Gene
Edwards, S. M., Kote-Jarai, Z., Meitz, J., Hamoudi, R., Hope, Q., Osin, P., Jackson, R., Southgate, C., Singh, R., Falconer, A., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/345310 · Cited by 366
BRCA2 germline mutations in male breast cancer cases and breast cancer families
Couch, F. J., Farid, L. M., DeShano, M. L., Tavtigian, S. V., Calzone, K., Campeau, L., Peng, Y., Bogden, B., Chen, Q., Neuhausen, S., et al. (1996) · Nature Genetics · doi:10.1038/ng0596-123 · Cited by 363
Population-based study of risk of breast cancer in carriers of BRCA2 mutation
Thorlacius, S., Struewing, J. P., Hartage, P., Olafsdottir, G. H., Sigvaldason, H., Tryggvadottir, L., Wacholder, S., Tulinius, H., & Eyfjörd, J. E. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03300-5 · Cited by 348
BRCA1 and BRCA2 Mutation Analysis of 208 Ashkenazi Jewish Women with Ovarian Cancer
Moslehi, R., Chu, W., Karlan, B., Fishman, D., Risch, H., Fields, A., Smotkin, D., Ben-David, Y., Rosenblatt, J., Russo, D., et al. (2000) · The American Journal of Human Genetics · doi:10.1086/302853 · Cited by 314
Self-citationFrequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families
Tonin, P., Weber, B., Offit, K., Couch, F., Rebbeck, T. R., Neuhausen, S., Godwin, A. K., Daly, M., Wagner-Costalos, J., Berman, D., et al. (1996) · Nature Medicine · doi:10.1038/nm1196-1179 · Cited by 313
Self-citationStudy of a single BRCA2 mutation with high carrier frequency in a small population.
Thorlacius, S., Sigurðsson, S., Bjarnadóttir, H., Ólafsdóttir, G. H., Jonasson, J. G., Tryggvadóttír, L., Tulinius, H., & Je, E. (1997) · Europe PMC (PubMed Central) · Cited by 294
Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population.
Friedman, L. S., Gayther, S. A., Kurosaki, T., Gordon, D., Noble, B., Casey, G., Ponder, B. A. J., & Anton‐Culver, H. (1997) · PubMed · Cited by 275
Mutation analysis of the BRCA2 gene in 49 site–specific breast cancer families
Phelan, C. M., Lancaster, J. M., Tonin, P., Gumbs, C., Cochran, C., Carter, R., Ghadirian, P., Perret, C., Moslehi, R., Dion, F., et al. (1996) · Nature Genetics · doi:10.1038/ng0596-120 · Cited by 257
Self-citationLal, G., Liu, G., Schmocker, B., Kaurah, P., Özçelik, H., Narod, S. A., Redston, M. S., & Gallinger, S. (2000) · PubMed · Cited by 231
Self-citationGermline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients
Özcelik, H., Schmocker, B., Nicola, N. D., Shi, X.-H., Langer, B., Moore, M., Taylor, B. R., Narod, S. A., Darlington, G., Andrulis, I. L., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-17 · Cited by 225
Self-citationHigh prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients.
Jóhannesdóttir, G., Guðmundsson, J., Bergþorsson, J. Þ., Arason, A., Agnarsson, B. A., Eiríksdóttir, G., Johannsson, O. T., Borg, Å., Ingvarsson, S., Easton, D. F., et al. (1996) · PubMed · Cited by 223
Fodor, F. H., Weston, A., Bleiweiss, I. J., McCurdy, L. D., Walsh, M. M., Tartter, P. I., Brower, S. T., & Eng, C. M. (1998) · The American Journal of Human Genetics · doi:10.1086/301903 · Cited by 220
BRCA1 and BRCA2 mutations in a population-based study of male breast cancer
Basham, V. M., Lipscombe, J. M., Ward, J. M., Gayther, S. A., Ponder, B. A., Easton, D. F., & Pharoah, P. D. (2001) · Breast Cancer Research · doi:10.1186/bcr419 · Cited by 191
Frontometaphyseal dysplasia: Neonatal radiographic diagnosis
Glass, R. B. J., & Rosenbaum, K. N. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320570102 · Cited by 189
Variation in BRCA1 cancer risks by mutation position.
Thompson, D. J., & Easton, D. F. (2002) · PubMed · Cited by 187
The BRC repeats are conserved in mammalian BRCA2 proteins
Bignell, G. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.1.53 · Cited by 174
Contribution of BRCA1 and BRCA2 Mutations to Breast and Ovarian Cancer in Pakistan
Liede, A., Malik, I. A., Aziz, Z., Rios, P. D. L., Kwan, E., & Narod, S. A. (2002) · The American Journal of Human Genetics · doi:10.1086/342506 · Cited by 159
Self-citationHaraldsson, K., Loman, N., Zhang, Q., Jóhannsson, Ó. Þ., Olsson, H. L., & Borg, Å. (1998) · PubMed · Cited by 144
Dorval, M., Patenaude, A. F., Schneider, K. A., Kieffer, S. A., DiGianni, L. M., Kalkbrenner, K. J., Bromberg, J. I., Basili, L. A., Calzone, K., Stopfer, J. E., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2135 · Cited by 143
Berman, D. B., Costalas, J. W., Schultz, D., Grana, G., Daly, M. B., & Godwin, A. K. (1996) · PubMed · Cited by 105
Liede, A., Metcalfe, K. A., Hanna, D., Hoodfar, E., Snyder, C., Durham, C. G., Lynch, H. T., & Narod, S. A. (2000) · The American Journal of Human Genetics · doi:10.1086/316907 · Cited by 104
Self-citationThe effect of a single BRCA2 mutation on cancer in Iceland
Tulinius, H., Ólafsdóttir, G. H., Sigvaldason, H., Arason, A., Barkardottir, R. B., Egilsson, V., Ogmundsdottir, H. M., Tryggvadóttír, L., Gudlaugsdottir, S., & Eyfjord, J. E. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.7.457 · Cited by 89
Csókay, B., Udvarhelyi, N., Sulyok, Z., et al. (1999) · PubMed · Cited by 79
Contribution of Germline Mutations in BRCA2 , P16 INK4A , P14 ARF and P15 to Uveal Melanoma
Hearle, N., Damato, B. E., Humphreys, J., Wixey, J., Green, H. E., Stone, J. G., Easton, D. F., & Houlston, R. S. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-0026 · Cited by 72
BRCA1 and BRCA2 have a limited role in familial prostate cancer.
Sinclair, C. S., Berry, R. M., Schaid, D. J., Thibodeau, S. N., & Couch, F. J. (2000) · PubMed · Cited by 69
Wilkens, E. P., Freije, D., Xu, J., Nusskern, D. R., Suzuki, H., Isaacs, S. D., Wiley, K. E., Bujnovszky, P., Meyers, D. A., Walsh, P. C., et al. (1999) · The Prostate · Cited by 63
The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel
Vazina, A., Baniel, J., Yaacobi, Y., Shtriker, A., Engelstein, D., Leibovitz, I., Zehavi, M., Sidi, A., Ramon, Y., Tischler, T., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1249 · Cited by 61
Lodder, L., Frets, P., Trijsburg, R. W., Tibben, A., Meijers-Heijboer, E. J., Duivenvoorden, H., Wagner, A., van der Meer, C. A., Devilee, P., Cornelisse, C., et al. (2001) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200668 · Cited by 58
Germline BRCA2 mutations in men with breast cancer
Mavraki, E., Gray, I., Bishop, D. T., et al. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.574 · Cited by 46
BRCA2 mutations in a population‐based series of patients with ocular melanoma
Scott, R. J., Vajdic, C. M., Armstrong, B. K., Ainsworth, C. J., Meldrum, C. J., Aitken, J. F., & Kricker, A. (2002) · International Journal of Cancer · doi:10.1002/ijc.10693 · Cited by 41
Predictive testing for BRCA1 and 2 mutations: a male contribution
Daly, P. A., Nolan, C., Green, A., Ormiston, W. J., Cody, N., McDevitt, T., O’Hici, B., Byrne, D., McDermott, E. W. M., Carney, D. N., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg164 · Cited by 39
Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer
Real, F. X., Malats, N., Lesca, G., Porta, M. S., Chopin, S., Lenoir, G., & Sinilnikova, O. M. (2002) · Gut · doi:10.1136/gut.50.5.653 · Cited by 32
Chen‐Shtoyerman, R., Figer, A., Fidder, H. H., Rath, P., Yeremin, L., Meir, S. B., Friedman, E., & Theodor, L. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1598 · Cited by 24
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V., Czito, B., Del Chiaro, M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0017 · Cited by 1,304
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Self-citationGenetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
Metadata
- Authors
- Liede, A., Karlan, B. Y., & Narod, S. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-02-15
- Volume
- 22
- Issue
- 4
- Pages
- 735-742
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2019983958
- Cited by
- 407
- References
- 56
- FWCI
- 12.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.